

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)

2. (Currently Amended) ~~The A substantially pure nucleic acid comprising of claim 1, wherein the nucleic acid comprises~~ a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:6.

3. (Currently Amended) A substantially pure nucleic acid that encodes a polypeptide that has one or more Helios biological activity selected from the group consisting of:
 - (a) the ability to form a dimer with a Helios, Aiolos or Ikaros polypeptide;
 - (b) the ability to bind DNA; and
 - (c) the ability to stimulate transcription from an Ikaros binding site,
wherein the nucleic acid hybridizes to the nucleotide sequence of SEQ ID NO:5 under high stringency conditions (i) or (ii):
 - (i) hybridization in 480 ml formamide, 240 ml 20x SSC, 10 ml 2 M Tris.Cl, pH 7.6, 10 ml 100x Denhardts solution, 50 ml deionized water, 200 ml 50% dextran sulfate, and 10 ml 10% SDS; and wash in 0.2x SSC and .1% sodium dodecyl sulfate (SDS); or
 - (ii) hybridization in 1% crystalline bovine serum albumin (BSA), 1 mM EDTA, 0.5 M NaHPO₄, pH 7.2, and 7% SDS; and wash in 1 mM Na₂EDTA, 40 mM NaHPO₄, pH 7.2, and 1% SDS at 65°C.

4. (Canceled)

5. (currently amended) A substantially pure nucleic acid ~~which (a) that~~ encodes a fragment of the polypeptide of SEQ ID NO: 6 of at least 60 amino acids in length. ~~and (b) hybridizes to the nucleotide sequence of SEQ ID NO:5 under high stringency conditions (i) or (ii):~~

~~(i) hybridization in 480 ml formamide, 240 ml 20x SSC, 10 ml 2 M Tris.Cl, pH 7.6, 10 ml 100x Denhardts solution, 50 ml deionized water, 200 ml 50% dextran sulfate, and 10 ml 10% SDS; and wash in 0.2x SSC and .1% sodium dodecyl sulfate (SDS); or~~

~~(ii) hybridization in 1% crystalline bovine serum albumin (BSA), 1 mM EDTA, 0.5 M NaHPO₄, pH 7.2, and 7% SDS; and wash in 1 mM Na₂EDTA, 40 mM NaHPO₄, pH 7.2, and 1% SDS at 65°C,~~

~~wherein the nucleic acid does not hybridize with an Ikaros gene or an Aiolos gene.~~

6-9 (Canceled)

10. (currently amended) A vector comprising the nucleic acid of any of claims 2, 3 or 5 1, 2, or 3.

11. (currently amended) A cell comprising the nucleic acid of any of claims 2, 3 or 5 1, 2, or 3.

12. (Canceled)

13. (Original) A method of manufacturing an Helios polypeptide comprising culturing the cell of claim 11 in a medium to express the Helios polypeptide.

14-20. (Canceled)

21. (currently amended) A substantially pure nucleic acid consisting of a nucleotide sequence encoding a polypeptide of SEQ ID NO: 6.

22-24. (canceled)

25. (New) A substantially pure nucleic acid comprising the coding sequence of SEQ ID NO:5.

26. (New) An oligonucleotide comprising between 30 and 150 contiguous nucleotides of SEQ ID NO: 6.

27. (New) The oligonucleotide of claim 26, further comprising a label group.

28. (New) The oligonucleotide of claim 27, wherein the label group is selected from the group consisting of: a radioisotope, a fluorescent compound, an enzyme, and an enzyme co-factor.